CDK4 and neoplasm: CDK4/6i as monotherapy reduced tumor growth over a period of 6 weeks, but both double and triple combinations inhibited growth to a greater extent (p = 0.02 and p = 0.01, respectively) and resulted in tumor regression (Fig. 3D and Supplementary Fig. S4C).